Caprock Group LLC Buys Shares of 11,363 Charles River Laboratories International, Inc. $CRL

Caprock Group LLC purchased a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 11,363 shares of the medical research company’s stock, valued at approximately $1,856,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of CRL. Neo Ivy Capital Management purchased a new position in Charles River Laboratories International during the second quarter worth about $29,000. Atlantic Union Bankshares Corp acquired a new position in shares of Charles River Laboratories International in the 3rd quarter worth approximately $31,000. Geneos Wealth Management Inc. increased its holdings in Charles River Laboratories International by 98.0% in the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 145 shares during the last quarter. Allworth Financial LP raised its position in Charles River Laboratories International by 172.7% in the second quarter. Allworth Financial LP now owns 300 shares of the medical research company’s stock valued at $45,000 after purchasing an additional 190 shares during the period. Finally, SJS Investment Consulting Inc. purchased a new stake in Charles River Laboratories International in the third quarter valued at approximately $48,000. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on CRL. Morgan Stanley set a $185.00 price objective on Charles River Laboratories International in a report on Monday, December 1st. Mizuho set a $215.00 target price on Charles River Laboratories International in a research report on Friday, January 9th. Argus set a $200.00 price target on shares of Charles River Laboratories International in a research report on Monday, November 17th. JPMorgan Chase & Co. lifted their price objective on shares of Charles River Laboratories International from $165.00 to $190.00 and gave the company a “neutral” rating in a report on Monday, December 15th. Finally, Robert W. Baird set a $224.00 target price on shares of Charles River Laboratories International in a research note on Friday, January 9th. Ten analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $209.46.

Charles River Laboratories International Stock Performance

Shares of CRL stock opened at $161.15 on Friday. The company has a market cap of $7.93 billion, a P/E ratio of -103.30, a PEG ratio of 4.76 and a beta of 1.63. The firm has a fifty day moving average price of $203.27 and a 200 day moving average price of $179.67. The company has a current ratio of 1.37, a quick ratio of 1.10 and a debt-to-equity ratio of 0.64. Charles River Laboratories International, Inc. has a 12 month low of $91.86 and a 12 month high of $228.88.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.